Opinion

Video

Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Panelists discuss how promising ongoing and upcoming clinical trials may reshape sequencing strategies in ALK+ non–small cell lung cancer (NSCLC).

Future Directions

  • Key Discussion Points:
  • Dr Lovly highlighted promising clinical trials that may reshape ALK+ NSCLC treatment sequencing strategies

Notable Expert Insights

  • Dr Dietrich provided critical analysis of the CROWN trial data and the implications of matching-adjusted indirect comparisons between different ALK inhibitors for clinical decision-making
  • Dr Lovly offered specialized perspective on resistance patterns and mutation-guided therapy selection, particularly incorporating emerging data on investigational agents like NVL-655
  • Elizabeth Castronovo contributed valuable real-world experience comparing clinical trial outcomes with observed patient responses and toxicity management approaches
  • Mary Grizzard emphasized patient-centered care considerations, highlighting education strategies and practical challenges faced during treatment transitions

The panelists collectively addressed the evolving treatment landscape for ALK+ NSCLC, emphasizing evidence-based approaches to optimize patient outcomes through appropriate therapy selection, sequencing strategies, and adverse event management.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Brian Slomovitz
Dr Sheela Rao
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo